Perez Kimberly, Del Rivero Jaydira, Kennedy Erin B, Basu Sandip, Chauhan Aman, Connolly Heidi M, Dasari Arvind N, Gangi Alexandra, Clarke Callisia N, Hallet Julie, Howe James R, Grady Erin, Ivanidze Jana, Mittra Erik S, White Sarah B, Raj Nitya P, Vijayvergia Namrata, Lewis Mark A, Chan Jennifer A, Kunz Pamela L, Mailman Josh, Arshad Junaid, Soares Heloisa P, Singh Simron, Chandrasekharan Chandrika, Soulen Michael C, Janson Eva Tiensuu, Halfdanarson Thorvardur R, Strosberg Jonathan R, Bergsland Emily K
Dana-Farber Cancer Institute, Boston, MA.
Center for Cancer Research, National Cancer Institute, Bethesda, MD.
JCO Oncol Pract. 2025 May 9:OP2500133. doi: 10.1200/OP-25-00133.
To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors.
ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice.
The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations.
Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
